Table 2 The multiple complications after cataract surgery in the ESRD and Controls.

From: Cataract surgery-related complications in patients with end-stage renal disease- a nationwide population-based study in Taiwan

 

Before matching

After matching

ESRD patients n (%) n = 454

Controls n (%) n = 24073

Adjusted ORa (95% CI)

P-value

ESRD patients n (%) n = 352

Controls n (%) n = 1760

Adjusted ORb (95% CI)

P-value

Corneal oedema

14 (3.08)

484 (2.01)

1.64 (0.96–2.81)

0.0711

12 (3.41)

41 (2.33)

1.57 (0.81–3.05)

0.1829

Glaucoma

40 (8.81)

2126 (8.83)

0.81 (0.58–1.13)

0.2135

12 (3.41)

55 (3.13)

1.07 (0.56–2.05)

0.8301

Endophthalmitis

1 (0.22)

81 (0.34)

0.89 (0.18–4.38)

0.8828

1 (0.28)

7 (0.40)

0.62 (0.07–5.17)

0.6544

VH

20 (4.41)

97 (0.48)

5.76 (3.42–9.71)

<0.0001

15 (4.26)

15 (0.85)

5.06 (2.36–10.87)

<0.0001

Retinal detachment

3 (0.66)

64 (0.27)

1.98 (0.66–5.93)

0.2204

3 (0.85)

5 (0.28)

3.21 (0.68–15.24)

0.1428

Intraocular lens dislocation

2 (0.44)

43 (0.18)

2.14 (0.60–7.63)

0.2426

2 (0.57)

2 (0.11)

4.90 (0.65–36.72)

0.1218

Dropped nucleus

10 (2.20)

157 (0.65)

2.65 (1.38–5.08)

0.0034

10 (2.84)

16 (0.91)

2.74 (1.20–6.27)

0.0170

Wound dehiscence

1 (0.22)

26 (0.11)

1.64 (0.33–8.14)

0.5481

1 (0.28)

2 (0.11)

3.26 (0.26–40.27)

0.3565

  1. Abbreviations: CI, confidence interval; ESRD, end stage renal disease; OR, odds ratio; VH, vitreous haemorrhage.
  2. aAdjusted by the summary of confounding variables in a single disease risk scores.
  3. bAdjusted by hospital level and use of antiplatelets or anticoagulants and according to the sample sizes, we used the Firth’s penalized likelihood approach.
Back to article page